True Care Biomedix Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: True Care Biomedix Pharmaceutical Export Portfolio Dataset — 2 Products, $1.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

True Care Biomedix — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.7M Trade | TransData Nexus

True Care Biomedix

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $1.7M Total Trade · DGFT Verified

True Care Biomedix is an Indian pharmaceutical exporter with a total trade value of $1.7M across 2 products in 2 therapeutic categories. Based on 34 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Docusate ($950.0K), Diphenhydramine ($709.8K), .

True Care Biomedix — Export Portfolio & Destination Treemap

True Care Biomedix pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is True Care Biomedix? — Company Overview & Market Position

True Care Biomedix is an Indian pharmaceutical exporter specializing in the development, manufacturing, and global supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2008, the company operates as a 100% Export Oriented Unit (E.O.U.) under the jurisdiction of the Directorate General of Foreign Trade (DGFT), India. Its manufacturing facilities are located in Gujarat, India, with the business office situated at 201, "TORAN", Vikas Nagar, Old Padra Main Road, Vadodara 390020, and the manufacturing site at College Road, Balasinor, Mahisagar – 388255. The company is registered under the Corporate Identification Number (CIN) provided by the Ministry of Corporate Affairs, India. While specific revenue figures are not publicly disclosed, True Care Biomedix has demonstrated a consistent export performance, with a total export value of $1.7 million USD and 34 shipments across two therapeutic categories between 2022 and 2026. The company employs a dedicated team committed to delivering high-quality pharmaceutical products globally.

What Does True Care Biomedix Export? — Product Portfolio Analysis

Top Products by Export Value

1Docusate$950.0K

Product Portfolio — Top 2 by Export Value

True Care Biomedix exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docusate	Gastrointestinal	$950.0K	19	10.3%	2
2	Diphenhydramine	Antihistamines & Allergy	$709.8K	15	2.2%	9

True Care Biomedix exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.7M. The top category is Gastrointestinal (57.2% of portfolio), followed by Antihistamines & Allergy (42.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

True Care Biomedix — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

True Care Biomedix operates state-of-the-art manufacturing facilities in Gujarat, India, adhering to current Good Manufacturing Practice (cGMP) standards. The manufacturing site in Balasinor, Mahisagar, is equipped to produce a wide range of solid oral dosage forms, including tablets and capsules, with a monthly production capacity of 200 million tablets and 50 million capsules. These facilities are designed to maintain the highest quality standards, featuring temperature- and dust-controlled environments to ensure product integrity. The company emphasizes energy conservation and efficient production strategies, utilizing high-quality materials to maximize productivity. All processes and equipment undergo rigorous validation to assure consistent quality, aligning with international and national regulations.

3Key Leadership

Specific details regarding the CEO, CFO, and other key executives of True Care Biomedix are not publicly disclosed. However, the company's leadership is characterized by a team of experienced professionals dedicated to upholding the company's mission of delivering high-quality pharmaceutical products globally. The management team emphasizes a system-driven organization, fostering ample opportunities for team members to contribute to the company's growth and success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does True Care Biomedix Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

True Care Biomedix's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Between 2022 and 2026, the company reported a total export value of $1.7 million USD across 34 shipments, with products spanning two therapeutic categories. The top five products exported include Docusate (57.2% of exports) and Diphenhydramine (42.8% of exports). The company's portfolio is entirely concentrated on these five products, indicating a strategic focus on specific therapeutic areas. While True Care Biomedix has demonstrated a consistent export performance, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements.

2Emerging Markets

True Care Biomedix's export data indicates a focus on specific therapeutic categories, with a significant portion of exports in the gastrointestinal and antihistamines & allergy segments. While the company's export activities are primarily directed towards these therapeutic areas, specific information regarding its penetration into emerging markets in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may facilitate access to these emerging markets.

True Care Biomedix — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding True Care Biomedix's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may include compliance with FDA standards. However, without publicly accessible records, a comprehensive assessment of the company's FDA status cannot be conducted.

2WHO & EU GMP

Specific information regarding True Care Biomedix's WHO prequalification, EU GMP certificates, and EDQM status is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may include compliance with WHO and EU GMP standards. However, without publicly accessible records, a comprehensive assessment of the company's certifications cannot be conducted.

3CDSCO & Indian Regulatory

True Care Biomedix — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

True Care Biomedix operates in the competitive landscape of finished pharmaceutical formulations, focusing on specific therapeutic areas such as gastrointestinal and antihistamines & allergy segments. While the company's export data indicates a concentrated portfolio, specific information regarding its top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may influence its competitive positioning.

2Key Differentiators

True Care Biomedix's key differentiators include its adherence to current Good Manufacturing Practice (cGMP) standards, ensuring high-quality pharmaceutical products. The company's status as a 100% Export Oriented Unit (E.O.U.) under the Directorate General of Foreign Trade (DGFT) reflects its commitment to international trade and compliance with export regulations. Additionally, the company's manufacturing facilities in Gujarat, India, are designed to maintain the highest quality standards, featuring temperature- and dust-controlled environments to ensure product integrity.

3Strategic Position

Buyer Due Diligence Brief — Evaluating True Care Biomedix as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Specific information regarding True Care Biomedix's overall track record, export volume and consistency, and reliability indicators is not publicly available. The company's adherence to cGMP standards and its status as a 100%

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — True Care Biomedix

How many pharmaceutical products does True Care Biomedix export from India?

True Care Biomedix exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Docusate ($950.0K), Diphenhydramine ($709.8K). Total export value is $1.7M.

What is True Care Biomedix's total pharmaceutical export value?

True Care Biomedix's total pharmaceutical export value is $1.7M, based on 34 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does True Care Biomedix cover?

True Care Biomedix exports across 2 therapeutic categories. The largest are Gastrointestinal (57.2%, 1 products), Antihistamines & Allergy (42.8%, 1 products).

Get Full True Care Biomedix Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.